This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Smith, S. E. Articles by Meldrum, B. S. Search for Related Content PubMed PubMed Citation Articles by Smith, S. E. Articles by Meldrum, B. S.

Stroke, Vol 23, 861-864, Copyright © 1992 by American Heart Association

ARTICLES

Cerebroprotective effect of a non-N-methyl-D-aspartate antagonist, GYKI 52466, after focal ischemia in the rat

SE Smith and BS Meldrum
Department of Neurology, Institute of Psychiatry, Denmark Hill, UK.

BACKGROUND AND PURPOSE: Cerebroprotection after the administration of N- methyl-D-aspartate antagonists has been well documented. The present study sought to determine whether a cerebroprotective effect could be achieved with the administration of a non-N-methyl-D-aspartate antagonist, GYKI 52466 (1-(4-aminophenyl)-4-methyl-7,8-methylene-dioxy- 5H-2,3-benzodiazep ine hydrochloride; molecular weight, 330) after middle cerebral artery occlusion in the rat. METHODS: Neurological deficit and infarct volume 24 hours after permanent left middle cerebral artery occlusion in Fischer rats (n = 7-13 per group per dose) were studied. Cerebral infarcts was visualized by the lack of reduction of 2,3,5-triphenyltetrazolium chloride. RESULTS: GYKI 52466 (10 mg.kg-1 i.p. at 0, 2, 4 hours) after middle cerebral artery occlusion had no effect on infarct volume. GYKI 52466 (10 mg.kg-1 i.v. for 5 minutes followed by 15 mg.kg-1.hr-1 i.v. for 2 hours immediately after middle cerebral artery occlusion reduced cortical infarct volume by 68% (from 69 mm3 in vehicle-treated to 22 mm3 in GYKI 52466-treated animals; p less than 0.05). A 1-hour delay before initiation of drug infusion resulted in a 48% reduction in cortical infarct volume (from 60 mm3 vehicle-treated rats to 31 mm3 in GYKI 52466-treated rats; p less than 0.05). A 2-hour delay before initiation of drug infusion had no effect on cortical infarct volume. Neurological deficits (with blinded assessment after 24 hours) were improved after immediate treatment and after delayed treatment (1 or 2 hours). CONCLUSIONS: The cerebroprotective effect of GYKI 52466 in the rat suggests a possible therapeutic role for non-N-methyl-D-aspartate antagonists given shortly after the onset of stroke.

This article has been cited by other articles:

				K. Ohno, R. Tsutsumi, N. Matsumoto, H. Yamashita, Y. Amada, J.-I. Shishikura, H. I. S.-I. Yatsugi, M. Okada, S. Sakamoto, and T. Yamaguchi Functional Characterization of YM928, a Novel Noncompetitive {alpha}-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA) Receptor Antagonist J. Pharmacol. Exp. Ther., July 1, 2003; 306(1): 66 - 72. [Abstract] [Full Text] [PDF]

				F. S. Menniti, A. M. Buchan, B. L. Chenard, D. J. Critchett, A. H. Ganong, V. Guanowsky, P. A. Seymour, and W. M. Welch CP-465,022, a Selective Noncompetitive AMPA Receptor Antagonist, Blocks AMPA Receptors but Is Not Neuroprotective In Vivo Stroke, January 1, 2003; 34(1): 171 - 176. [Abstract] [Full Text] [PDF]

				G. P. Schielke, N. C. Kupina, P. A. Boxer, C. F. Bigge, D. F. Welty, and C. Iadecola The Neuroprotective Effect of the Novel AMPA Receptor Antagonist PD152247 (PNQX) in Temporary Focal Ischemia in the Rat • Editorial Comment Stroke, July 1, 1999; 30(7): 1472 - 1477. [Abstract] [Full Text] [PDF]

				T. Weiser, M. Brenner, R. Palluk, W. D. Bechtel, A. Ceci, A. Brambilla, H. A. Ensinger, A. Sagrada, and M. Wienrich BIIR 561 CL: A Novel Combined Antagonist of alpha -Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid Receptors and Voltage-Dependent Sodium Channels with Anticonvulsive and Neuroprotective Properties J. Pharmacol. Exp. Ther., June 1, 1999; 289(3): 1343 - 1349. [Abstract] [Full Text]

				J. W. McDonald, T. Bhattacharyya, S. L. Sensi, D. Lobner, H. S. Ying, L. M.T. Canzoniero, and D. W. Choi Extracellular Acidity Potentiates AMPA Receptor-Mediated Cortical Neuronal Death J. Neurosci., August 15, 1998; 18(16): 6290 - 6299. [Abstract] [Full Text] [PDF]

				P. Bittigau and C. Ikonomidou Topical Review: Glutamate in Neurologic Diseases J Child Neurol, November 1, 1997; 12(8): 471 - 485. [Abstract] [PDF]

				L. Belayev, R. Busto, W. Zhao, and M. D. Ginsberg HU-211, a Novel Noncompetitive N-Methyl-D-Aspartate Antagonist, Improves Neurological Deficit and Reduces Infarct Volume After Reversible Focal Cerebral Ischemia in the Rat Stroke, December 1, 1995; 26(12): 2313 - 2320. [Abstract] [Full Text]

				J. Castillo, F. Martinez, E. Corredera, J.M. Aldrey, and M. Noya Amino Acid Transmitters in Patients With Headache During the Acute Phase of Cerebrovascular Ischemic Disease Stroke, November 1, 1995; 26(11): 2035 - 2039. [Abstract] [Full Text]

				J. R. Brorson, C. J. Marcuccilli, and R. J. Miller Delayed Antagonism of Calpain Reduces Excitotoxicity in Cultured Neurons Stroke, July 1, 1995; 26(7): 1259 - 1267. [Abstract] [Full Text]

				M. D. Ginsberg REVIEW {blacksquare} : Neuroprotection in Brain Ischemia: An Update (Part I Neuroscientist, March 1, 1995; 1(2): 95 - 103. [Abstract] [PDF]

				S. E. Smith and B. S. Meldrum Cerebroprotective Effect of Lamotrigine After Focal Ischemia in Rats Stroke, January 1, 1995; 26(1): 117 - 122. [Abstract] [Full Text]

				S. A. Lipton and P. A. Rosenberg Excitatory Amino Acids as a Final Common Pathway for Neurologic Disorders N. Engl. J. Med., March 3, 1994; 330(9): 613 - 622. [Full Text]